3/3
06:06 pm
srpt
Sarepta Therapeutics (SRPT) was given a new $25.00 price target by Loop Capital.
Low
Report
Sarepta Therapeutics (SRPT) was given a new $25.00 price target by Loop Capital.
3/3
02:12 pm
srpt
Sarepta Therapeutics (SRPT) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Low
Report
Sarepta Therapeutics (SRPT) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
3/2
09:31 am
srpt
Sarepta Therapeutics (SRPT) had its price target lowered by Wedbush from $34.00 to $29.00. They now have an "outperform" rating on the stock.
Low
Report
Sarepta Therapeutics (SRPT) had its price target lowered by Wedbush from $34.00 to $29.00. They now have an "outperform" rating on the stock.
3/2
08:03 am
srpt
Sarepta Therapeutics (SRPT) had its "sell" rating reaffirmed by HC Wainwright. They now have a $5.00 price target on the stock.
Low
Report
Sarepta Therapeutics (SRPT) had its "sell" rating reaffirmed by HC Wainwright. They now have a $5.00 price target on the stock.
3/1
04:40 am
srpt
Wells Fargo Cuts PT on Sarepta Therapeutics (SRPT) to $38 From $45 [Yahoo! Finance]
Low
Report
Wells Fargo Cuts PT on Sarepta Therapeutics (SRPT) to $38 From $45 [Yahoo! Finance]
2/28
11:40 pm
srpt
Why Sarepta Therapeutics (SRPT) Is Down 11.2% After CEO Retirement Plan And Japan Gene Therapy Launch - And What's Next [Yahoo! Finance]
Low
Report
Why Sarepta Therapeutics (SRPT) Is Down 11.2% After CEO Retirement Plan And Japan Gene Therapy Launch - And What's Next [Yahoo! Finance]
2/28
12:10 pm
srpt
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory [Yahoo! Finance]
Low
Report
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory [Yahoo! Finance]
2/28
09:41 am
srpt
Sarepta CEO To Jump Ship After 'Tumultuous' Year [Yahoo! Finance]
Low
Report
Sarepta CEO To Jump Ship After 'Tumultuous' Year [Yahoo! Finance]
2/27
01:11 pm
srpt
Sarepta Therapeutics (SRPT) had its price target lowered by Wells Fargo & Company from $45.00 to $38.00. They now have an "overweight" rating on the stock.
Low
Report
Sarepta Therapeutics (SRPT) had its price target lowered by Wells Fargo & Company from $45.00 to $38.00. They now have an "overweight" rating on the stock.
2/27
09:15 am
srpt
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program [Yahoo! Finance]
Low
Report
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program [Yahoo! Finance]
2/27
09:00 am
srpt
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
Low
Report
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
2/26
08:44 am
srpt
Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress [Yahoo! Finance]
Medium
Report
Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress [Yahoo! Finance]
2/26
08:30 am
srpt
Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress
Medium
Report
Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress
2/26
03:27 am
srpt
Sarepta Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Sarepta Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
2/25
07:14 pm
srpt
Sarepta (SRPT) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Sarepta (SRPT) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
2/25
04:05 pm
srpt
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments
Medium
Report
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments
2/24
09:07 am
srpt
Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan
Medium
Report
Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan
2/24
08:55 am
srpt
Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
Medium
Report
Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
2/24
08:30 am
srpt
Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Medium
Report
Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
2/14
07:09 pm
srpt
Does Sarepta's Move Into Huntington's siRNA Trials Reframe the Bull Case For Sarepta Therapeutics (SRPT)? [Yahoo! Finance]
Low
Report
Does Sarepta's Move Into Huntington's siRNA Trials Reframe the Bull Case For Sarepta Therapeutics (SRPT)? [Yahoo! Finance]
2/14
07:09 pm
srpt
Assessing Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Volatility [Yahoo! Finance]
Low
Report
Assessing Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Volatility [Yahoo! Finance]
2/11
09:06 am
srpt
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results [Yahoo! Finance]
Low
Report
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results [Yahoo! Finance]
2/11
08:30 am
srpt
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results
Low
Report
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results
2/4
08:30 am
srpt
Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease
Medium
Report
Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease
2/1
07:03 pm
srpt
Sarepta's Elevidys Data Underscore Long Term Duchenne Therapy Durability [Yahoo! Finance]
Low
Report
Sarepta's Elevidys Data Underscore Long Term Duchenne Therapy Durability [Yahoo! Finance]